Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.30 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2614422 | 0.80 | THRB (0.59) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL5850936 | 0.80 | KDM4E (0.39) | MEN1MAPTKMT2AKDM4E | |
| Iodide SCHEMBL6330992 | 0.79 | THRB (0.62) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL5850305 | 0.76 | KDM4E (0.52) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL5849880 | 0.74 | CYP1A1 (0.48) | MEN1LMNAMAPTKMT2AKDM4E | |
| SCHEMBL7532656 | 0.74 | MEN1 (0.40) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL4604770 | 0.74 | MAPT (0.44) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL4615093 | 0.74 | ESPL1 (0.43) | MEN1LMNAMAPTTHRBHTT | |
| Iodide SCHEMBL5850358 | 0.74 | KCNH2 (0.45) | MEN1LMNAMAPTTHRBHTT | |
| SCHEMBL5850212 | 0.72 | MEN1 (0.58) | MEN1LMNAMAPTTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056348-B2 | 5-aryl-1,3,3-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibers | WELLA AG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | Wella GmbH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | INMT, KRT18, IPO5 | MEN1 1991/4885LMNA 27/4885MAPT 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.